The Pharmacotherapy of Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
Potent inhibitors of 5-hydroxytryptamine (5-HT) reuptake have clearly been established as the first-line pharmacotherapy for treatment of obsessive-compulsive disorder (OCD). Although a variety of tricyclic antidepressants and monoamine oxidase inhibitors have similar efficacy in the treatment of depression and panic disorder, potent blockade of 5-HT transport appears to be a prerequisite for effective treatment of OCD. Addiing agents that enhance 5-HT neurotransmission to ongoing treatment in patients whose OCD is refractory to 5-HT reuptake inhibitors has not yielded impressive results. However, the addition of low-dose dopamine (DA) antagonists to the regimens of treatment-resistant patients appears to be a potentially useful strategy for the specific subgroup of OCD patients with a comorbid chronic tic disorder such as Tourette's syndrome. Because of the toxicity associated with neuroleptics, a time-limited trial of those agents, with reassessment at regular intervals, is indicated. Pharmacologic studies suggest that both the 5-HT and DA systems may be critical to the treatment and possibly the pathophysiology of OCD. Zusammenfassung Potentielle 5-HT-Wiederaufhahmehemmer haben sich als Mittel der Wahl in der Pharmakotherapie von Zwangsneurosen (obsessive-compulsive disorder=OCD) bewährt. Obwohl eine Anzahl trizyklischer Antidepressiva und MAO-Hemmer in der Behandlung von Depressionen und Paniksyndromen ähnlich wirksam sind, scheint eine starke Blockierung des 5-HT-Transports die Voraussetzung für eine wirksame OCD-Behandlung zu sein. Die zusätzliche Verabreichung von Präparaten, die die 5-HT-Neurotransmission verstärken, erzielte keinen eindrucksvollen Erfolg bei bereits in Behandlung befindlichen Patienten, deren OCD gegen 5-HT-Wiederaufnahmehemmer resistent war. Eine zusätzliche Gabe von Dopaminantagonisten (DA) in niedriger Dosierung zu der Medikamentierung behandlungsresistenter Patienten scheint jedoch zweckmäßig bei Patienten mit gleichzeitigem Ticsyndrom (z. B. Gilles de la Tourette-Syndrom) zu sein. Wegen der Toxizität der Neuroleptika ist eine zeitliche Begrenzung ihrer Verabreichung indiziert, wobei regelmäßig eine Nachprüfung erfolgen sollte. Pharmakologische Studien deuten darauf hin, daß sowohl das 5-HT- als auch das DA-System für die Behandlung und möglicherweise Pathophysiologie der OCD von kritischer Bedeutung sein können.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
Pathophysiology of obsessive–compulsive disorder
Aouizerate, B., Guehl, D., Cuny, E., Rougier, A., Bioulac, B., Tignol, J., & Burbaud, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.004 · Cited by 341
Berridge, K. C., Aldridge, J. W., Houchard, K. R., & Zhuang, X. (2005) · BMC Biology · doi:10.1186/1741-7007-3-4 · Cited by 309
Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder
Zohar, J., Judge, R., & Ocd Paroxetine Study Investigators (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.4.468 · Cited by 272
Karayiorgou, M., Sobin, C., Blundell, M. L., Galke, B. L., Malinova, L., Goldberg, P., Ott, J., & Gogos, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00319-9 · Cited by 263
Metadata
- Authors
- McDougle, C., Goodman, W., & Price, L.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1993-05
- Volume
- 26
- Issue
- S 1
- Pages
- 24-29
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2030313712
- Cited by
- 78
- References
- 0
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Pharmacotherapy of Obsessive-Compulsive Disorder. https://app.cochat.ai/papers/10.1055/s-2007-1014373
- The paper
- McDougle, C., Goodman, W., & Price, L. (1993). The Pharmacotherapy of Obsessive-Compulsive Disorder. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-1014373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.